1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

Ongoing Dossier Updates Seen As Big REACH For Industry – Study

 
• By Jamie Hammon

The requirement for registrants to update REACH chemical dossiers when changes occur or new information comes to light represents an endless road, and many companies are running out of gas, suggests a third-party report commissioned by ECHA. Moreover, there's confusion about what needs to be updated, when, and who is responsible, the authors say, extending recommendations for improvements.

Empty endless highway through the volcanic landscape with copy space

Companies in the EU fail to update REACH chemical dossiers because they don’t know they’re supposed to, are unsure of who is responsible and in many cases lack the resources, a third-party study found.

The European Chemicals Agency commissioned the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.